Secukinumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Secukinumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
280
Registered trials
381
Result records
28
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Secukinumab can convert its Monoclonal antibody profile and IL-17A biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Secukinumab (query alias: secukinumab) |
|---|---|
| Modality / target | Monoclonal antibody; IL-17A; IL-17A inhibitors |
| Highest global status | Approved |
| Originator | Novartis Pharma AG |
| Active developers | Novartis Pharmaceuticals Corp., Beijing Novartis Pharma Co. Ltd., Novartis AG |
The MCP disease footprint includes Pustular psoriasis, Ankylosing Spondylitis, Axial Spondyloarthritis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07485764 | Phase 4 | Not yet recruiting | 186 | Proportion of Participants Achieving PASI75 at Week 24 |
| NCT07489573 | Phase 4 | Recruiting | 36 | Percentage of participants achieving HiSCR50 at Week 16 |
| ChiCTR2600127293 | Early Phase 1 | Not yet recruiting | 64 | Time to First Clinical Relapse within 48 Weeks(TFR) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Secukinumab for Giant Cell Arteritis
Phase 3; n=353; evaluation: Negative. Reported fields: SR(52-week) = 19.4 % ; SR(52-week) = 25.6 % ; SR(52-week) = 16.9 %
COMPARATIVE REAL-WORLD RISK OF CANDIDIASIS IN ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB VERSUS IXEKIZUMAB
Not Applicable; n=1836; evaluation: Positive. Reported fields: Candidiasis = 2.3 % ; Candidiasis = 1.4 %
CHARACTERISTICS INFLUENCING THE PREVENTION OF PSORIATIC ARTHRITIS WITH SECUKINUMAB IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: 5-YEAR REAL-WORLD RESULTS FROM THE SERENA STUDY
Not Applicable; n=1334; evaluation: Positive. Reported fields: PASI(5 years; 90/100) = 67.3 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Secukinumab addresses Pustular psoriasis, Ankylosing Spondylitis, Axial Spondyloarthritis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 28 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: IL-17A records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-07-01 | 君实生物与复星万邦就偌考奇拜单抗（IL-17A）达成研发和商业化合作 | NDA/BLA | US$31.6M upfront; US$165.6M milestones |
| 2025-11-10 | Bio-Thera Solutions Expands Partnership with Dr. Reddy’s through an Exclusive Commercialization and License Agreement for BAT2306, a Proposed Biosimilar Candidate to Cosentyx® (Secukinumab), in Southeast Asia | NDA/BLA | Financial terms not disclosed |
| 2025-10-08 | Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis | Preclinical | US$2,000.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists”. The milestone feed surfaced a patent-application signal described as “Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
